Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups

P. B. McGlave, P. De Fabritiis, A. Deisseroth, J. Goldman, M. Barnett, J. Reiffers, B. Simonsson, A. Carella, D. Aeppli

Research output: Contribution to journalArticle

Abstract

Summary. Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven years. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.

Original languageEnglish
Pages (from-to)1486-1488
Number of pages3
JournalLancet
Volume343
Issue number8911
DOIs
Publication statusPublished - Jun 11 1994

Fingerprint

Autografts
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplants
Tissue Donors
Bone Marrow
Unrelated Donors
Hematologic Neoplasms
Patient Care
Stem Cells
Therapeutics
Transplantation
Survival
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McGlave, P. B., De Fabritiis, P., Deisseroth, A., Goldman, J., Barnett, M., Reiffers, J., ... Aeppli, D. (1994). Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet, 343(8911), 1486-1488. https://doi.org/10.1016/S0140-6736(94)92589-5

Autologous transplants for chronic myelogenous leukaemia : results from eight transplant groups. / McGlave, P. B.; De Fabritiis, P.; Deisseroth, A.; Goldman, J.; Barnett, M.; Reiffers, J.; Simonsson, B.; Carella, A.; Aeppli, D.

In: Lancet, Vol. 343, No. 8911, 11.06.1994, p. 1486-1488.

Research output: Contribution to journalArticle

McGlave, PB, De Fabritiis, P, Deisseroth, A, Goldman, J, Barnett, M, Reiffers, J, Simonsson, B, Carella, A & Aeppli, D 1994, 'Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups', Lancet, vol. 343, no. 8911, pp. 1486-1488. https://doi.org/10.1016/S0140-6736(94)92589-5
McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 1994 Jun 11;343(8911):1486-1488. https://doi.org/10.1016/S0140-6736(94)92589-5
McGlave, P. B. ; De Fabritiis, P. ; Deisseroth, A. ; Goldman, J. ; Barnett, M. ; Reiffers, J. ; Simonsson, B. ; Carella, A. ; Aeppli, D. / Autologous transplants for chronic myelogenous leukaemia : results from eight transplant groups. In: Lancet. 1994 ; Vol. 343, No. 8911. pp. 1486-1488.
@article{64519c89328b485886d02f3a52128a37,
title = "Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups",
abstract = "Summary. Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven years. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.",
author = "McGlave, {P. B.} and {De Fabritiis}, P. and A. Deisseroth and J. Goldman and M. Barnett and J. Reiffers and B. Simonsson and A. Carella and D. Aeppli",
year = "1994",
month = "6",
day = "11",
doi = "10.1016/S0140-6736(94)92589-5",
language = "English",
volume = "343",
pages = "1486--1488",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8911",

}

TY - JOUR

T1 - Autologous transplants for chronic myelogenous leukaemia

T2 - results from eight transplant groups

AU - McGlave, P. B.

AU - De Fabritiis, P.

AU - Deisseroth, A.

AU - Goldman, J.

AU - Barnett, M.

AU - Reiffers, J.

AU - Simonsson, B.

AU - Carella, A.

AU - Aeppli, D.

PY - 1994/6/11

Y1 - 1994/6/11

N2 - Summary. Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven years. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.

AB - Summary. Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven years. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.

UR - http://www.scopus.com/inward/record.url?scp=0028283040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283040&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(94)92589-5

DO - 10.1016/S0140-6736(94)92589-5

M3 - Article

C2 - 7911185

AN - SCOPUS:0028283040

VL - 343

SP - 1486

EP - 1488

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8911

ER -